Page last updated: 2024-11-01
nortriptyline and Gastric Stasis
nortriptyline has been researched along with Gastric Stasis in 1 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "To determine whether treatment with nortriptyline results in symptomatic improvement in patients with idiopathic gastroparesis." | 9.17 | Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. ( Abell, TL; Farrugia, G; Hamilton, F; Hasler, WL; Koch, KL; Lee, L; McCallum, RW; Nguyen, L; Parkman, HP; Pasricha, PJ; Sarosiek, I; Snape, WJ; Tonascia, J; Unalp-Arida, A; Van Natta, ML, 2013) |
| "To determine whether treatment with nortriptyline results in symptomatic improvement in patients with idiopathic gastroparesis." | 5.17 | Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. ( Abell, TL; Farrugia, G; Hamilton, F; Hasler, WL; Koch, KL; Lee, L; McCallum, RW; Nguyen, L; Parkman, HP; Pasricha, PJ; Sarosiek, I; Snape, WJ; Tonascia, J; Unalp-Arida, A; Van Natta, ML, 2013) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Parkman, HP | 1 |
| Van Natta, ML | 1 |
| Abell, TL | 1 |
| McCallum, RW | 1 |
| Sarosiek, I | 1 |
| Nguyen, L | 1 |
| Snape, WJ | 1 |
| Koch, KL | 1 |
| Hasler, WL | 1 |
| Farrugia, G | 1 |
| Lee, L | 1 |
| Unalp-Arida, A | 1 |
| Tonascia, J | 1 |
| Hamilton, F | 1 |
| Pasricha, PJ | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)[NCT00765895] | Phase 3 | 130 participants (Actual) | Interventional | 2009-01-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits
A decrease from the baseline Gastroparesis Cardinal Symptom Index (GCSI) score (sum of the 9 individual symptom scores) of at least 50% on any two consecutive follow-up visits during the 15 week treatment period with maximum tolerated study drug dose. The total score ranges from 0-45 with higher scores indicating greater symptom severity. (NCT00765895)
Timeframe: at end of treatment, 15 weeks from baseline assessment
| Intervention | participants (Number) |
|---|
| Nortriptyline | 15 |
| Placebo | 14 |
Trials
1 trial available for nortriptyline and Gastric Stasis